Natco and Mylan get favourable decision for patent dispute in US Court

Natco Pharma announced that the United States Court of Appeals for the Federal Circuit has affirmed the District of Delaware's decision that Teva's Copaxone 40 mg/ml dosing patents are invalid as obvious. The Federal Circuit also affirmed today the final written decisions issued by the Patent Trial and Appeal Board (PTAB) in three inter partes reviews filed by Natco's marketing partner, Mylan, related to the same patents.

These were the last remaining patent infringement cases Mylan was defending in the U.S. relating to Glatiramer Acetate Injection 40mg/ml.

The invalidated patents are U.S. Patent Numbers 8,232,250; 8,399,413; 8,969,302; and 9,155,776, which are owned by Veda Research & Development Co. and licensed to Teva Pharmaceuticals Industries.

Powered by Capital Market - Live News